Natco Pharma
Indian pharmaceutical company
From Wikipedia, the free encyclopedia
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations, active pharmaceutical ingredients and agrochemical products.[4] It is a major producer of branded oncology medicines[5] cardiology, diabetology and other pharma specialty drugs[6] at affordable prices.[7][8][9][10]
| |
Company type | Public |
|---|---|
| NSE: NATCOPHARM BSE: 524816 | |
| Industry | Pharmaceuticals |
| Founded | 1981 |
| Founder | VC Nannapaneni |
| Headquarters | , India |
Area served | Global |
Key people | VC Nannapaneni (Chairman and MD)[1] Rajeev Nannapaneni (CEO and Vice Chairman)[2] |
| Revenue |  ₹4,784 crore (US$510 million) (2025) |
| ₹2,550 crore (US$270 million) (2025) | |
| ₹1,883 crore (US$200 million) (2025) | |
| Website | natcopharma.co.in |
| Footnotes / references Financials as of 31 March 2025[update].[3] | |
History
Natco Pharma was founded in 1981 by V C Nannapaneni. In 1983, operations commenced at manufacturing facility at Nagarjunasagar. In 1986, the company's chemical division started at Mekaguda near Hyderabad.[citation needed]
In 2008, Natco Pharma filed its first paragraph IV filing in the US with the USFDA,[11] In 2012, Natco Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.[6] In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.[11]
In 2016, Natco Pharma launched the first Tamiflu capsule in the US market.[12] In 2017, Natco Pharma launched a generic version of blood cancer drug Pomalidomide in the United States.[13] In 2019, Natco Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district, Andhra Pradesh.[14]
In 2025, Natco Pharma completed the acquisition of a 35.75% stake in Adcock Ingram, a South African pharmaceutical company, for approximately US$226 million. The acquisition resulted in the delisting of Adcock Ingram from the Johannesburg Stock Exchange.[15][16][17]